GPR84 and metabolic dysfunction-associated steatohepatitis: In support of this, a recent study demonstrated that MCFAs effectively suppress lipotoxicity and NASH progression by modulating the immune response through G‐protein‐coupled receptor 84 (GPR84) (Ohue‐Kitano et al., 2023).